IP Library Granted Patent US 11,426,463
Granted Patent B2
US 11,426,463 · App. 14/403,549 · Granted Aug 30, 2022

Compositions and methods for biophotonic bone reconstruction

Inventors: Nikolaos Loupis (Athens, GR); Remigio Piergallini (Grottammare Ascoli Piceno, IT)
Assignee: KLOX TECHNOLOGIES INC.
A61K41/0057A61K41/00A61L24/0015A61L24/0084A61L27/46A61L27/54A61N5/062C08K3/32C08K5/0041C08K5/1545A61K6/838A61L2300/442A61N2005/0663C08K2003/325
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,463
App. No.
14/403,549
Granted
Aug 30, 2022
Kind
B2
Abstract

This disclosure provides biophotonic compositions comprising a photoactivator, a calcium phosphate mineral, hyaluronic acid and optionally glucosamine. The compositions of this disclosure have utility in the augmentation, repair and/or regeneration of bone when used in conjunction with actinic light of a wavelength absorbed by the photoactivator.

Claims (38)

1. A biophotonic composition comprising:

a photoactivator which can absorb and emit light;

a calcium phosphate mineral having an average particle size of between about 150 nm and about 500 nm;

hyaluronic acid; and

glucosamine;

wherein the hyaluronic acid and the glucosamine components are about 70-90% by weight of the total weight of the composition;

wherein the biophotonic composition is non-photo-polymerized and is suitable for administration at a site of bone reconstruction;

wherein the biophotonic composition emits fluorescence upon being illuminated by actinic light for a period of between about 1 second and 30 seconds; and

wherein the biophotonic composition does not include an oxidant.

2. The biophotonic composition of claim 1 , wherein the photoactivator is present in an amount of at least about 0.2% by weight of the total weight of the biophotonic composition.

3. The biophotonic composition claim 1 , wherein the photoactivator is present in an amount of about 0.2-1% by weight of the total weight of the biophotonic composition.

4. The biophotonic composition of claim 1 , wherein the photoactivator is a xanthene dye or a fluorescein derivative.

5. The biophotonic composition of claim 4 , wherein the fluorescein derivative is eosin Y.

6. The biophotonic composition of claim 1 , wherein the calcium phosphate mineral comprises hydroxyapatite.

7. The biophotonic composition of claim 1 , wherein the calcium phosphate mineral is about 10-30% by weight of the total weight of the biophotonic composition.

8. The biophotonic composition of claim 1 , wherein the hyaluronic acid is cross-linked hyaluronic acid.

9. The biophotonic composition of claim 1 , wherein the hyaluronic acid is a non cross-linked hyaluronic acid.

10. The biophotonic composition of claim 9 , wherein the hyaluronic acid has a molecular weight of between about 1 million Dalton and 2 million Dalton, about 1.2 million to about 1.8 million Dalton, or about 1.7 million Dalton.

11. The biophotonic composition of claim 1 , wherein the hyaluronic acid is about 5-90% by weight of the total weight of the biophotonic composition.

12. The biophotonic composition of claim 1 , wherein the ratio of calcium phosphate mineral to hyaluronic acid is about 1:9, 1.5:8.5, 2:8, 2.5:7.5 or 3:7.

13. The biophotonic composition of claim 1 , wherein the ratio of calcium phosphate mineral to hyaluronic acid is about 6:4, 6.5:3.5 or 7:3.

14. The biophotonic composition of claim 1 , wherein the ratio of calcium phosphate mineral to hyaluronic acid is about 8:2, 8.5:1.5, 9:1 or 9.5:0.5.

15. The biophotonic composition of claim 1 , wherein the ratio of hyaluronic acid to glucosamine is about 1:1, 3:2, 7:3, 4:1; or 9:1.

16. The biophotonic composition of claim 1 , wherein the ratio of calcium phosphate mineral to hyaluronic acid and glucosamine is about 1:9, 1.5:8.5, 2:8, 2.5:7.5 or 3:7.

17. The biophotonic composition of claim 1 , wherein the ratio of calcium phosphate mineral to hyaluronic acid and glucosamine is about 6:4, 6.5:3.5 or 7:3.

18. The biophotonic composition of claim 1 , wherein the ratio of calcium phosphate mineral to hyaluronic acid and glucosamine is about 8:2, 8.5:1.5, 9:1 or 9.5:0.5.

19. The biophotonic composition of claim 1 , wherein the biophotonic composition does not include one or more of triethanolamine (TEA), N-vinyl-2-pyrrolidone (NVP), or N-vinyl caprolactam (NVC).

20. The biophotonic composition of claim 1 , wherein the biophotonic composition does not include a 15 amino acid residue peptide irreversibly bound to the calcium phosphate mineral.

21. The biophotonic composition of claim 20 , wherein the calcium phosphate mineral comprises hydroxyapatite.

22. A method for augmenting, repairing or regenerating bone, comprising:

a) providing a biophotonic composition of claim 1 ;

b) applying a layer of the biophotonic composition to a bone tissue site;

c) irradiating the biophotonic composition with actinic light; and d) repeating steps (b) and (c) at least once.

23. The method of claim 22 , wherein each layer of step (b) has a thickness of about 0.5-4 mm.

24. The method of claim 22 , wherein the biophotonic composition is irradiated for less than about 5 minutes.

25. The method of claim 22 , wherein the biophotonic composition is irradiated with light having a wavelength in the range of about 400-700 nm.

26. The method of claim 22 , wherein the biophotonic composition promotes detectable bone growth in the bone tissue site in about 3 months.

27. The method of claim 22 , wherein the biophotonic composition used for a first layer has a different ratio of calcium phosphate mineral to hyaluronic acid and/or glucosamine than the biophotonic composition used for a second layer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2023
From: KLOX TECHNOLOGIES INC.
To: FLE INTERNATIONAL S.R.L.
Reel/Frame 063214/0370 →
CONFIRMATORY ASSIGNMENT Recorded Dec 22, 2014
From: LOUPIS, NIKOLAOS; PIERGALLINI, REMIGIO
To: KLOX TECHNOLOGIES INC.
Reel/Frame 034693/0477 →
Continuity (3)
Provisional Application 61777894 · Mar 12, 2013
Provisional Application 61653101 · May 30, 2012
Related Publication 20150119789A1 · Apr 30, 2015